Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration Resistant to Bevacizumab and Ranibizumab.

Kim, Jong Ha; Cho, Nam Chun; Kim, Woo Jin

doi:2015.56.9.1359

J Korean Ophthalmol Soc > Volume 56(9); 2015 > Article

Original Article

Journal of the Korean Ophthalmological Society 2015;56(9):1359-1364.
DOI: https://doi.org/10.3341/jkos.2015.56.9.1359 Published online September 15, 2015.

Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration Resistant to Bevacizumab and Ranibizumab.

Jong Ha Kim, Nam Chun Cho, Woo Jin Kim

¹Department of Ophthalmology, Chonbuk National University Medical School, Jeonju, Korea. alberts123@hanmail.net
²Research Institute of Clinical Medicine of Chonbuk National University-Biomedical Research Institute of Chonbuk National University Hospital, Jeonju, Korea.

베바시주맙과 라니비주맙에 반응 없는 삼출성 나이관련황반변성에서 애플리버셉트 주입술의 효과

김종하¹⋅조남천^1,2⋅김우진^1,2

전북대학교 의학전문대학원 안과학교실¹, 전북대학교 임상의학연구소-전북대학교병원 의생명연구원²

Received: 15 May 2015 • Revised: 19 June 2015 • Accepted: 14 August 2015

Abstract

PURPOSE
To evaluate outcomes of intravitreal aflibercept in cases resistant to bevacizumab and ranibizumab in neovascular age-related macular degeneration. METHODS: Twenty patients with neovascular age-related macular generation who were resistant to treatment with bevacizumab and ranibizumab were evaluated. After switching to aflibercept the best corrected visual acuity (BCVA) and central retinal thickness (CRT) were compared at baseline and at 1 month after injection. Additionally, changes in the intraretinal fluid, subretinal fluid and pigment epithelial detachment were evaluated. RESULTS: The mean BCVA was 0.83 +/- 0.56 log MAR and the mean CRT was 294.20 +/- 12.99 microm before aflibercept treatment. After switching to aflibercept the mean BCVA was 0.86 +/- 0.61 log MAR with no statistical difference (p = 0.406) and the mean CRT was decreased to 232.45 +/- 12.05 microm (p = 0.011). After 1 month of aflibercept injections, a reduction of intraretinal fluid in 4 eyes (80%), reduction of subretinal fluid in 11 eyes (78.6%) and reduction of pigment epithelial detachment in 5 eyes (50%) were observed. Increases in fluid or new lesions were not observed. CONCLUSIONS: Aflibercept injection appears beneficial in patients with neovascular age-related macular generation who are resistant to bavacizumab and ranibizumab treatment.

Key Words: Aflibercept;Neovascular age-related macular degeneration;Treatment-resistant